abstract: In recent years the emerging importance of estrogen signaling in males in addition to its major role in the female reproductive system became highlighted. Aromatase is the key enzyme for synthesis of estrogens from androgens and is responsible for controlling the androgen/estrogen ratio. Inhibition of aromatase gene expression can be achieved in different ways and is important for the treatment of several estrogen-dependent diseases, such as breast cancer in females or gynecomastia/breast cancer in males, or for non-tumorigenic conditions like precocious puberty and the induction of ovulation. The inhibition of aromatase could also serve as a tool for studying the role of estrogens during development or adulthood. Using transgenic models, we are able to analyze in more detail the involvement of aromatase in the molecular mechanisms underlying the essential balance of the androgen/estrogen ratio. In this review we focus on male phenotype characterization in the aromatase overexpressing transgenic murine models and how these models can further serve as a tool for aromatase inhibitor research.
Introduction
Estrogens are well known as the essential hormones for reproduction in females. Estrogen actions are mediated via genomic effects by the presence of estrogen receptors (ERa and b), estrogen-regulated transcription factors (coactivators and corepressors) and rapid nongenomic effects (Coleman and Smith, 2001; Hall et al., 2001; Smith and O'Malley, 2004) . The androgen/estrogen ratio has been shown to be crucial for the induction of ovulation and apoptosis of the oocytes (Kafy and Tulandi, 2007; Mitwally and Casper, 2001 , 2002 . With the findings on the significance of estrogen deficiency in men from the clinical studies (Bouillon, 2004; Carani et al., 1997; Deladoey et al., 1999; Herrmann, 2002; Maffei, 2004; Morishima et al., 1995) , and from the milestone studies on the establishment of the ERa (aERKO) (Lubahn et al., 1993) , ERb (bERKO) (Krege et al., 1998) and aromatase knockout (ArkO) (Fisher et al., 1998) murine models in the late 1990s, the requirement of estrogen and its actions in males also has become an accepted concept nowadays.
Aromatase and its gene in vertebrates
The androgen/estrogen ratio in vertebrates is controlled by the intracellular presence and activity of aromatase, a member of the cytochrome P450 family and a product of the P450arom/cyp19 gene. Aromatase is the enzyme responsible for catalyzing androgens to form the phenolic A ring of estrogens in the final step of the steroid hormones biosynthesis de novo. The human P450arom gene was first cloned in Simpson's group (Evans et al., 1987) . The identities of the derived amino acid sequences of P450arom from rat, mouse, bovine, chicken and trout compared with the human sequence are 77, 81, 73, 52 and 86%, respectively (Simpson et al., 1994) .
P450arom is expressed in a wide variety of tissues, depending on the species considered. In human, for example, the enzyme has been found in ovary, testis, placenta, brain, liver, adipose tissue and skin, as well as in a number of tissues in the fetus . Tissue-specific promoters regulate the P450arom gene at the transcriptional levels in the placenta, adipose tissue, brain and in gonads (Mahendroo, 1993) and are described elsewhere [for a review, please see ]. Regardless of the tissuespecific expression patterns of aromatase, the protein product of P450arom gene has so far been found the same. Due to the important role of aromatase, the control of aromatase gene expression at all levels: mRNA, protein, enzymatic activity and functional has been considered as pivotal, not only for the treatment of breast cancer (Miller, 1996) , but also in males, such as in the cases of gynecomastia Bulun et al., 1999a) or prostate cancers (De Coster et al., 1996) . Treating males with aromatase inhibitors (AIs) also may provide some local androgenization. In this review, we will briefly analyze the importance of the AIs and the aromatase effects on androgen/estrogen balance in biologically relevant TG murine models, which may serve as a useful tool for AI studies.
Aromatase inhibitors
AIs are used as an established method of endocrine therapy in estrogen-dependent malignant tumor growth in the inhibition of estrogen biosynthesis, accomplished by the selective blockage of aromatase, in order to avoid possible side effects (Seralini and Moslemi, 2001) . Specific AIs have been accepted as the first line agent in postmenopausal breast cancer, where the risk of acquiring endometrial carcinoma after antiestrogen treatments could be avoided by AI treatments (Killackey et al., 1985) . They could also be used successfully for male breast cancer, which is rare but does also exist, and also for treating gynecomastia Bulun et al., 1999a) . Testicular tumors are the leading cancer in males between 20 and 40 years of age, accounting for 20% of neoplasms in this age group (Adami et al., 1994; Ahmed, 1999; Moller, 2001) . Leydig cell tumors induced by aromatase overexpresssion have been shown in TG mice overexpressing aromatase (Fowler et al., 2000; Li et al., 2003) . AIs could also be tested for their potential use in hepatocellular carcinoma, where ER has been found (Villa et al., 1995; Villa et al., 1996; Villa et al., 2003) . Aromatase expression has been found in around 35% of human cervical carcinomas, while no aromatase expression was detected in precancerous or normal cervical tissues, which could be associated with the increases in estrogen receptors (ER-a and ER-b) and a decrease in the progesterone receptor levels, suggesting that in situ estrogen signaling via ER may be involved in the tumor growth (Nair et al., 2005) . Aromatase expression in cervical carcinomas thus also opens the possibility for their future eventual treatment with AIs. AIs could also be tested for non-tumorigenic cases like precocious puberty in boys and girls (Feuillan et al., 1986; Feuillan et al., 1993; Feuillan et al., 1999; Feuillan et al., 2007) . There are reports where the clinical relevance of local aromatase expression in endometriosis was exemplified by a successful treatment of an unusually aggressive form of recurrent endometriosis in a postmenopausal woman using an AI (Bulun et al., 1999b) . AIs have been shown to be very useful as alternative drugs to clomiphene citrate or gonadotropins for ovulation induction or for inducing superovulation (Holzer et al., 2006; Kafy and Tulandi, 2007; Mitwally and Casper, 2002 . Besides these above mentioned cases, AI effects could also be tested where the estrogen action is known, such as on lipid, insulin metabolism, protection of atherosclerosis, body weight gain and bone remodeling brain and neuronal functions, male reproductive tract and reproduction, namely on the testosterone production.
Aromatase null TG mice
Before focussing on aromatse overexpressing models and their potential use in AI studies, we discuss briefly on the ArKO model, as this model represents the other side of the coin, that is, a system devoid of estrogens. Analysis of this model could provide, albeit an extreme indication of what complete systematic blockage (via an AI) may ultimately be achieved or could be expected. Three independent groups have described the generation of ArKO mice (Fisher et al., 1998; Honda et al., 1998; Toda et al., 2001) . In general, the phenotypes of the different mice appear to be similar. One of the groups reported that the homozygous mutant male mice are initially fully fertile (Fisher et al., 1998) , but their fertility decreased significantly with advancing age (Robertson et al., 2001) . The other two groups reported that not all ArKO males are infertile (Honda et al., 1998; Toda et al., 2001) . The reason for these differences is not clear. It could be possible that other estrogenic steroid metabolites compensate for the lack of E2 and may affect the development of the male reproductive system (Toda et al., 2001) .
ArKO mice lacking a functional aromatase enzyme were generated by targeted disruption of the P450arom gene. Female ArKO mice at 9 weeks of age displayed underdeveloped external genitalia and uteri. Ovaries contained numerous follicles with abundant granulosa cells and evidence of antrum formation that appeared arrested before ovulation. No corpora lutea were present. Additionally, the stroma was hyperplastic with structures that appeared to be atretic follicles. Development of the mammary glands approximated that of a prepubertal female. Male ArKO mice of the same age revealed essentially normal internal anatomy but with enlargement of the male accessory sex glands because of increased content of secreted material. The testes appeared normal. Male ArKO mice are capable of breeding and produce litters of approximately average size. Whereas serum estradiol levels were at the limit of detection, testosterone levels were elevated, as were the levels of follicle-stimulating hormone and luteinizing hormone. The ArKO male mouse showed shortened femur length and bone undermineralization. Male ArKO mice testes at the age of 12 months demonstrated arrest of spermatogenesis at the level of round spermatids and Leydig cell hyperplasia. ArKO mice also exhibit evidence of insulin resistance and visceral adiposity (Fisher et al., 1998; Honda et al., 1998; Toda et al., 2001 ).
Generation of the aromatase overexpression mouse models for potential AI research Estrogens and androgens have been shown to be both crucial to determine biological function in a tissue-and gender-specific manner [for a review (Sharpe, 1997) ] Thus it is very likely that the adequate balance in the androgen/estrogen ratio is an important clinically relevant factor. In order to understand the physiological and pathophysiological roles of androgen/estrogen balance, two significant aromatase overexpressing TG mouse models have been produced (1) aromatase over expressing mice under the MMTV promoter (int-5/aromatase) (Tekmal et al., 1996) and (2) the mouse model with an imbalance in sex hormone metabolism by the expression of human aromatase gene under the human ubiquitin c promoter (AROMþ) .
Before describing these two models, we would also like to mention the estrogen sulfotransferase (EST) knockout mouse model (Qian et al., 2001) and the xenograft models (Brodie et al., 1999) for in vivo AI studies. In the xenograft model, tumors are grown in ovariectomized female immunodeficient mice from MCF-7 breast cancer cells transfected with aromatase gene, which therefore can synthesize and as well as respond to estrogen (Brodie et al., 1999) . This xenograft model is a rather easy model to establish and a good tool for studying the AIs. It has to be noted here that the xenograft models do have their weaker sides too. There are reports on many agents with promising activity in xenograft models producing disappointing results when subjected to clinical phase studies [for a review, see (Sharpless and Depinh, 2006) ]. There also exists a considerable controversy regarding the value of xenograft models (Suggitt and Bibby, 2005) . In comparison to xenograft models, animal tumor models provide an opportunity for precise investigation of genetic, molecular, hormonal and cellular changes of neoplastic transformation at different stages and, moreover, resembles human diseases for prevention, diagnostic screening and treatment (Vanderhyden et al., 2003) .
The EST knockout TG murine model also has the potential also to reflect the estrogen overexpression effects in a murine model. An estrogen metabolic enzyme, EST deficient mice have been developed through targeted disruption of the EST gene (Qian et al., 2001) . These knockout males were fertile and phenotypically normal initially at 2 months of age, but developed age-dependent (12 months of age or older) Leydig cell hypertrophy/hyperplasia and seminiferous tubule damage with reduced sperm motility by 80% and produced smaller litters compared with age-matched wild-type males (Qian et al., 2001) , probably due to the local estrogen action (Qian et al., 2001) . These findings might establish a role for EST in the male reproductive system and may further indicate that this model also might serve as a model for studying the AIs.
Aromatase over expressing mice under the MMTV promoter (int-5/aromatase) Clinically, aromatase was reported in very low quantities in normal human mammary gland and overexpressed in more than 70% of mammary gland tumors (Miller, 1991) . It has also been shown that local estrogen actions are the most critical in supporting the growth of hormone-dependent human breast cancers (Miller and O'Neill, 1987) . Tekmal et al. (1996) developed an aromatase overexpressing mouse model under the mouse mammary tumor virus promoter (MMTV) (int-5/aromatase). Their goal was to test the role of breasttissue estrogen in initiation of breast cancer by developing this TG model. The MMTV promoter is typically activated at puberty, especially in the male and female reproductive tissues (Tekmal et al., 1996) .
All the overexpressing int-5/aromatase TG virgin and postlactational female mice showed various histological abnormalities, leading to the enlargement of 40% of ducts, of which 65% had hyperplastic lesions, 20% had dysplastic lesions and 15% had fibroadenoma lesions (Tekmal et al., 1996) . Overexpression of int-5/aromatase in involuted mammary glands of TG females induced hyperplasia in 75-80% of ducts and glands that exhibit a range of morphological abnormalities (Tekmal et al., 1996) . The authors claimed that early and continued exposure of mammary epithelium to estrogen in int-5/aromatase overexpression mice predispose mammary tissue to preneoplastic changes, which may, in turn, increased the risk of developing neoplasia (Keshava et al., 2001; Tekmal et al., 1996; Tekmal et al., 1999) . The mammary gland findings from the int-5/ aromatase overexpression mice may support clinical and experimental data suggesting that early estrogen exposure may increase the breast cancer risk in human Tekmal et al., 1996; Tekmal et al., 1999) . Preneoplastic and neoplastic changes induced in 12-mo-old virgin TG int-5/aromatase female mammary glands as a result of aromatase overexpression was completely abrogated with the administration of AI, letrozole (5 mg s.c./animal in 100 ml 0.3% hydroxypropyl cellulose in phosphate buffered saline/day) (Tekmal et al., 1999) . The Tekmal group further tried a 10-fold lower dose of letrozole (0.5 mg letrozole s.c./animal/day) treatment on subsequent mammary growth and biochemical changes in these animals in order to test for eventual use of low dose letrozole as a chemopreventive drug for potential future mammary gland cancer patients (Luthra et al., 2003; Mandava et al., 2001) . They found that low dose letrozole had no effect on normal physiology as indicated by no significant changes in estradiol or follicle stimulating hormone levels or in estrogen responsive genes such as progesterone receptor and lactoferrin in the uterine tissue . They also suggested that this very low dose AI (letrozole) could prevent the aromatase overexpression-induced changes in the mammary glands .
In int-5/aromatase male mice, about half of the male TG mice were infertile and/or had larger than normal testicles, where histological analysis showed the mice to have unilateral or bilateral Leydig cell tumors, (Fowler et al., 2000) . Expressions of aromatase and estrogen receptors were very high in testicular tissue with 2-fold higher serum estradiol levels, and also upregulated estrogen-regulated genes involved in cell cycle in int-5/aromatase mice compared with nontransgenic mice (Fowler et al., 2000) . The authors suggested that overexpression of aromatase in int-5/aromatase results in increased estrogen production leading putatively to the induction of testicular Leydig cell tumors (Fowler et al., 2000; Mandava et al., 2001) . No phenotype characteristics had been shown for bone, urogenital system, pituitary or adrenals in these int-5/aromatase TG mice.
Aromatase over expressing mice under the ubiquitin C promoter (AROM1)
The AROMþ TG mice was generated initially by expressing the human aromatase gene under the universal human ubiquitin c promoter in the FVB/N background, which we have well characterized Li et al., 2002; Li et al., 2003; Li et al., 2004; Li et al., 2006; Peng et al., 2004; Streng et al., 2002) . AROMþ mice represented overall a multitude of structural and functional alterations in the male reproductive organs such as cryptorchidism, Leydig cell hyperplasia, disrupted spermatogenesis and infertility, but no significant female phenotype . These mice showed elevated serum estradiol and prolactin concentrations, but significantly decreased testosterone levels. For the urinary tract system, these mice developed infravesical obstruction associated with the rhabdosphincter atrophy and rudimentary accessory sex glands . The mammary gland in AROMþ males undergo a ductal and alveolar development morphologically resembling terminally differentiated female mammary glands, and express several signaling proteins typical for female mammary glands . Some of the abnormalities seen in AROMþ mice are similar to those described in both mice and humans exposed to diethylstilbestrol (DES) in utero (McLachlan et al., 1975; McLachlan et al., 1980) . The distribution of aromatase mRNA transgene level expression in AROMþ mice was strongest for the testis, and lower levels were detected in extragonadal tissues like mammary glands, heart, brain, bladder and liver ). Very recently we have generated the aromatase 
Table I
Genotypic general comparison between the two existing aromatase overexpressing TG mouse models: AROM1 (human aromatase gene under the human ubiquitin c promoter) Li et al., 2002; Li et al., 2003; Li et al., 2004; Li et al., 2006; Peng et al., 2004; Streng et al., 2002) and int-5/aromatase (human aromatase gene under the mouse MMTV) (Fowler et al., 2000; Gill et al., 2001; Kirma et al., 2001; Mandava et al., 2001; Tekmal et al., 1996; Tekmal et al., 1999) and aromatase inhibition (AI) induced treatment effects in AROM1 Streng et al., 2002) and int-5/aromatase Tekmal et al., 1999 overexpressing TG mice in C57Bl/6J background by doing the microinjections and embryo transfers to C57Bl females directly. This experiment was done in order to check the differential gene susceptibility effects by changing the genetic background. In C57Bl background aromatase overexpressing TG mice (which is under extensive phenotype characterization process now), we have observed severe cryptorchidism with inguinal hernia phenotype already at 2-mo of age (Li and Rahman, 2008 also Lin et al., unpublished data) in comparison to AROMþ mice where it was found at 8-10 mo . Upon characterization process, we have found that aromatase overexpressing males of C57Bl background (n ¼ 8) develop severe bladder outlet obstruction by the age of 8 mo causing death due to uremia with 100% incidence (n ¼ 8) (Lin et al. unpublished data) . We are currently characterizing the pituitary, mammary gland and adrenal phenotype in these C57Bl background aromatase overexpressing males. Hereby, we will summarize the AI treatment effects that we have achieved by treating 4-mo-old AROMþ TG males for a time period of 6 weeks with 10 mg finrozole p.o./in 0.25% carboxylmethyl cellulose was solubilized in deionized water/day/24 h/kg b.w. . Six-week AI treatment increased or normalized all the measured impairments caused by the E2/T ratio in 4-mo-old AROMþ males, such as the reduced body and organ weights, testicular and seminal vesicle, and also reduced the increased adrenal and pituitary weights . The cryptorchidism presented at 4-mo-old AROMþTG males descended 100% to scrotum, arrested spermatogenesis presented in placebo treated mice returned to complete spermatogenesis and number and size of the Leydig cells were reduced after the AI treatment . The finrozole treatment successfully reversed the alteration in the urodynamics and rhabdosphincter of adult AROMþ male mice and also additionally shown in the DES-exposed rats which also developed infravesical obstruction associated with the rhabdosphincter atrophy and rudimentary accessory sex glands as in AROMþ males . Morphologically the alveolar structure and the majority of the tertiary side branches of the ducts did not appear after the fenrozole treatments, whereas the differentiated mammary glands underwent involution in AROMþ placebo treated males . No significant differences could be found in the ERa expression, but the number of ER beta positive epithelial cells decreased after finrozole treatment. Another interesting finding was that the androgen receptor (AR) was strongly expressed in the alveolar epithelium of the mammary gland in finrozole treated AROMþ males, whereas no AR expression could be detected in the alveolar epithelium of placebo treated AROMþ males . Table I represents a genotypic general comparison between the aromatase overexpressing TG murine models and the AI induced treatments effects in these murine TG models.
Conclusions and future directions
Aromatase overexpression under the MMTV promoter (int-5/aromatase) emphasized the exclusive role of estrogens in mammary glands overgrowth, pathophysiology and finally mammary gland neoplasia. The MMTV promoter gets activated during the puberty in male and female reproductive tissues. This late activation of the MMTV promoter could be the reason for the late onset of gynecomastia in the males (3 mo) compared with AROMþ mice (as early as 20 days). Aromatase overexpression under the human ubiquitin promoter imitated the estrogen excess (occurring mainly in males) by showing the overall pathophysiological effects of chronically elevated systemic estrogens. Int-5/aromatase mice may serve as a good TG murine model for studying the female mammary gland tumors, gynecomastia and testicular Leydig cell tumors in males and as a good testing model for different AIs. Whereas, the AROMþ mouse model can serve as a model for studying the signal transduction pathways and transcriptional regulatory mechanisms that control differentiation and involution in the mammary glands. AROMþ model further can be used for studying the physio/pathological events occurring in the mammary glands of men who develop gynecomastia. AROMþ male TG mice could also serve as an ideal tool for testing the tissuespecific/selective new generation of AIs in the treatment of the dysfunctions in males associated with misbalanced androgen to estrogen ratio, such as pituitary adenoma, testicular dysfunction and gynecomastia (caused as the side effect of androgen ablation in prostate cancer patients). It might be quite beneficial to analyze the AI treatment effects in different in-and out-breed mouse genetic backgrounds, as the genetic susceptibility effects on the phenotype and might reveal interesting molecular mechanism of AI actions. Analysis of different strategies of aromatase inhibition with different classes of compounds in these aromatase overexpression TG models may reveal further information on estrogen-dependent disease treatments in females and in males, and also in understanding the molecular mechanisms and function of the cytochrome P450 enzyme.
